Atalay S, van den Reek JM, Otero ME, Njoo MD, Mommers JM, Ossenkoppele PM, et al. Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study. Acta Derm Venereol [Internet]. 2020 Dec. 1 [cited 2026 May 10];100(19):1-7. Available from: https://medicaljournalssweden.se/actadv/article/view/1863